Timing of cataract surgery in patients with giant cell arteritis

Autor: Joseph W Fong, Joseph G. Chacko
Rok vydání: 2021
Předmět:
Zdroj: Journal of Cataract and Refractive Surgery. 47:83-86
ISSN: 1873-4502
0886-3350
DOI: 10.1097/j.jcrs.0000000000000392
Popis: Purpose To determine a safe timeframe and parameters for performing cataract surgery following diagnosis and treatment of giant cell arteritis (GCA). Setting Single institution in the United States. Design Retrospective chart review. Methods This retrospective study used ICD-9/10 and Current Procedural Terminology codes to identify all patients with biopsy-proven GCA who underwent cataract surgery from 2005 to 2019 at a single institution. Excluded from the study were patients whose date of biopsy diagnosis or dose of corticosteroids at the time of cataract surgery was unknown. Results Chart review identified 10 patients (15 eyes) that met inclusion criteria; 80% of patients were female, and mean age was 74.4 years. Two patients had a history of arteritic ischemic optic neuropathy. There were no perioperative or postoperative complications in the 15 eyes that underwent cataract surgery with varying doses of prednisone at the time of surgery (1 to 25 mg daily prednisone +/- 10 to 25 mg weekly methotrexate; median prednisone dose of 10.75 mg) and varying time from biopsy diagnosis of GCA to surgery of at least 7 months (median 13.75 months). Conclusions Cataract surgery appeared safe for GCA patients on varying doses of prednisone at time of surgery at least 7 months from time of biopsy diagnosis. There is a need for a larger cohort of data from neuro-ophthalmologists and cataract surgeons nationally to establish guidelines for safe cataract surgery in GCA patients.
Databáze: OpenAIRE